DGAP-News

Minapharm Pharmaceuticals: RDIF and Minapharm Agree to Produce Over 40 Million Doses of the Sputnik V Vaccine in Egypt - Seite 3

Minapharm Pharmaceuticals is a leading pharmaceutical company in Egypt and the Middle East and the premier biopharmaceutical company in Africa with over 20 years of experience in cellular and bioprocess engineering. Headquartered in Cairo, Minapharm commercializes over 100 life-saving and life-enhancing products ranging from small molecules to complex genetically-engineered proteins, with an impressive immunotherapy pipeline. Minapharm's wholly owned Berlin-based subsidiary, ProBioGen AG, is a world-renowned contract development and manufacturing organisation (CDMO), a cell line-engineering specialist and a provider of proprietary protein and viral vector technologies to large pharma and the global biotech industry. Minapharm has established an integrated business model making it to-date the only gene-to-market biopharmaceutical company in the region. Minapharm employs a collective workforce of over 1400 and is listed on the Cairo and Alexandria stock exchange (Symbol: MIPH). Further information can be found at www.minapharm.com

Contacts

Russian Direct Investment Fund
Alexey Urazov
Director for External Communications
[phone]
[e-mail]                               

Hudson Sandler
Andrew Leach / Maria Shiryaevskaya
[phone]

Minapharm Pharmaceuticals
Dina Soliman
Director of Strategic Operations
[phone]
[e-mail]
 

---

22.04.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

---

Language:	English
Company:	Minapharm Pharmaceuticals
	2T Takseem Asmaa Fahmy Ard El Golf
	002002 Heliopolis Cairo
	Egypt
Internet:	www.minapharm.com
EQS News ID:	1187427

End of News	DGAP News Service

1187427  22.04.2021